[
    [
        {
            "time": "2023-10-05",
            "original_text": "Cramer Remix: Alphabet has broken this troubling trend after reporting earnings",
            "features": {
                "keywords": [
                    "Alphabet",
                    "earnings",
                    "troubling trend",
                    "broken"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Cramer Remix: Alphabet has broken this troubling trend after reporting earnings",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Pullback in Abbott Labs Gives Buyers Another Chance",
            "features": {
                "keywords": [
                    "Abbott Labs",
                    "pullback",
                    "buyers",
                    "chance"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pullback in Abbott Labs Gives Buyers Another Chance",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo",
            "features": {
                "keywords": [
                    "Agios",
                    "FDA",
                    "approval",
                    "Leukemia",
                    "Tibsovo"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]